Cardinal Health raises FY25 EPS guidance to $7.85-$8
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...
Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...
Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health Inc. closed 2.50% below its 52-week high of $131.00, which the company reached on January 27th.
Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...
Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback